Skip To Main Content
Parameswaran Hari on Muck Rack

Parameswaran Hari

As seen in: Nature, Wiley, The BMJ, Educational Studies, The New England Journal of Medicine, Healio, CURE Magazine, ONCOLOGY journal, Future Medicine, The ASCO Post and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Parameswaran

Contact Parameswaran, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Targeting PI3K decreases trogocytosis-mediated CAR T cell fratricide

|
By Tarang Sharma, Maday Galeana Figueroa, Kishan Kumar Nyati, Ravi Shah, Meera Mohan, Parameswaran Hari, Tim Luetkens, Sabarinath Venniyil Radhakrishnan
| Nature Verified
To the Editor, CAR T cell-mediated trogocytosis (CMT) is a proposed mechanism of tumor immune evasion, in which the cognate interaction between CAR T cells and tumor cells results in the transfer of target antigen from the tumor cell surface to the CAR T cell. In addition to the emergence of antigen-negative target cells, antigen-positive CAR T cells become the targets of other CAR T cells in a process called fratricide (Fig. 1a).
Open in Who Shared Issue with article?

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

|
By Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo
| The BMJ Verified
Immune cell therapies and immune cell engineering Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Open in Who Shared Issue with article?

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk - Blood Cancer Journal

|
By Natalie S. Callander, Jonathan Kaufman, Jacob P. Laubach, Timothy Schmidt, Brandi N. Reeves, Binod Dhakal, Saurabh Chhabra, Bhagirathbhai Dholaria, Parameswaran Hari, Sarah A Holstein, Andrzej J. Jakubowiak, Luciano Costa Verified, Saad Usmani, Paul Richardson
| Nature Verified
Abstract In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).
Open in Who Shared Issue with article?
See all 24 licensed articles (31 Total)